NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

罕見疾病用醫藥品的全球市場

Orphan Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 997882
出版日期 內容資訊 英文 278 Pages
商品交期: 最快1-2個工作天內
價格
罕見疾病用醫藥品的全球市場 Orphan Drugs
出版日期: 2021年04月01日內容資訊: 英文 278 Pages
簡介

全球罕見疾病用醫藥品的市場規模,預計在分析期間(2020年∼2027年)將以12.2%的年複合成長率增長,從2020年的1,655億美元,到2027年達到3,714億美元。

本報告所分析的市場區隔之一的生技藥品部門,分析期間中預計將以11.5%的年複合成長率增長,達到2,173億美元。

本報告提供全球罕見疾病用醫藥品市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corp.
  • CEL-SCI Corporation
  • Concordia International Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corp.,
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck Serono SA
  • Novartis AG
  • Pfizer Inc.
  • Recordati S.p.A.
  • Sanofi SA
  • Shire Plc.
  • Vertex Pharmaceuticals

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:140公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7443

Abstract:

Global Orphan Drugs Market to Reach $371.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Orphan Drugs estimated at US$165.5 Billion in the year 2020, is projected to reach a revised size of US$371.4 Billion by 2027, growing at aCAGR of 12.2% over the period 2020-2027. Biologics, one of the segments analyzed in the report, is projected to record 11.5% CAGR and reach US$217.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Biologics segment is readjusted to a revised 13.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $48.8 Billion, While China is Forecast to Grow at 11.8% CAGR

The Orphan Drugs market in the U.S. is estimated at US$48.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$65.2 Billion by the year 2027 trailing a CAGR of 11.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.9% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Select Competitors (Total 140 Featured) -

  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corp.
  • CEL-SCI Corporation
  • Concordia International Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corp.,
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck Serono SA
  • Novartis AG
  • Pfizer Inc.
  • Recordati S.p.A.
  • Sanofi SA
  • Shire Plc.
  • Vertex Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • A Prelude
    • Recent Market Activity
    • Increasing Adoption of Orphan Drugs by Manufacturers
    • The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry
    • Major Orphan Drugs Legislations Worldwide
    • Orphan Drugs Market on a Rapid Growth Trajectory
    • Select Major Organizations Dealing with Rare Diseases in the US, Canada, and EU
    • Incentives for Orphan Drug Designation Products in the US, EU, and Japan
    • Market Challenges
    • Obstacles for Conducting Orphan Drug Research
    • Competition
    • Orphan Drugs Remain Strong in the Pharmaceutical Pipeline
    • Important Orphan Drugs in Pipeline
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • AbbVie, Inc. (USA)
    • Actelion Pharmaceuticals Ltd. (Switzerland)
    • Alexion Pharmaceuticals, Inc. (USA)
    • Amgen, Inc. (USA)
    • AstraZeneca Plc. (UK)
    • Bayer AG (Germany)
    • Biogen Inc. (USA)
    • BioMarin Pharmaceutical Inc. (USA)
    • Boehringer Ingelheim GmbH (Germany)
    • Bristol-Myers Squibb Company (USA)
    • Celgene Corp. (USA)
    • CEL-SCI Corporation (USA)
    • Concordia International Corp. (Canada)
    • Eli Lilly and Company (USA)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Johnson & Johnson (USA)
    • Merck & Co., Inc. (USA)
    • Merck Serono International S.A. (Germany)
    • Merck Serono International S.A. (Germany)
    • Novartis AG (Switzerland)
    • Pfizer, Inc. (USA)
    • Recordati S.p.A. (Italy)
    • Orphan Europe (France)
    • Shire Plc. (Ireland)
    • Sanofi SA (France)
    • Genzyme Corp. (USA)
    • Vertex Pharmaceuticals (USA)
  • 3. MARKET TRENDS & DRIVERS
    • Regulatory Incentives - A Push in the Right Direction
    • Growing Unmet Medical Needs - Fulfilling the Gap
    • Rising Incidence of Rare Forms of Cancer - Opportunities Galore
    • Select Orphan Drugs for Cancer
    • Rise in Incidence of Renal Cell Carcinoma
    • Unmet Needs in AML
    • Aging Population Offers Growth Potential
    • Pre-Symptomatic Screening to Expand Market Base
    • Asia's Rising Awareness and Growing Population to Drive Sales
    • Drug Repurposing Provides Therapies for Rare Diseases
    • The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges
    • Interest of Major Pharmaceutical Firms Signal a Shift in Commercial Dynamics
    • Mergers and Acquisitions Drive Market Growth
    • Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016
    • Growing Scrutiny over Skyrocketing Prices
    • Orphan Drugs with High Prices: 2016
    • Medical Advancements Foster Growth
    • Full Reimbursements Critical for Spurring Uptake of High-Priced Orphan Drugs
    • Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs
    • Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis
    • Increasing Patient Engagement - The PAG Trend
    • Gene Therapy and Bioprocessing Preferred over Chronic Therapies
    • Companies Developing Gene Therapies
    • International Collaboration - The Way Forward
    • CNS Therapeutics to Gain Focus in the Orphan Drugs Market
    • Manufacturers Target Orphan Indications to Curtail Competition in Broader Indications
    • Manufacturers Use Orphan Disease to Target Larger Therapeutic Indications
    • Treating Autism - The Next Big Thing?
    • Sequencing Technology - The New Research Tool for Orphan Drugs
    • Innovations in Biotechnology - A Boon for Orphan Drug Research
    • Aging Gene Linked to Myeloma
    • Antibody with Potential to Treat Multiple Myeloma
    • Potential Treatment for Cystic Fibrosis Patients Infected with Mycobacterium abscessus
    • Genetic Variants to Improve Treatment of Non-small Cell Lung Cancer
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Non-Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 25: USA Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 31: Canada Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 34: Canada Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 37: Japan Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 40: Japan Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 43: China Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 46: China Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 49: Europe Current & Future Analysis for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 58: France Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 61: France Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 64: Germany Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 67: Germany Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 70: Italy Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 73: Italy Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 76: UK Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 79: UK Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Europe 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 85: Rest of Europe Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Europe 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 88: Asia-Pacific Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Asia-Pacific Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Asia-Pacific 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 91: Asia-Pacific Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Asia-Pacific Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Asia-Pacific 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 94: Rest of World Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of World Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of World 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2020 & 2027
    • TABLE 97: Rest of World Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of World Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of World 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Cardiovascular and Other Disease Types for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 140